Boston Scientific Corp (BSX) has been the focus of various investment firms lately.
Western Financial Corp CA and
Fortitude Family Office LLC, amongst others, actively increased their positions in BSX. Conversely, certain firms like
Community Trust & Investment Co. and
Sapient Capital LLC reduced their holdings. The company’s
stock has also seen heavy trading. Rating firms like
Needham,
Jefferies,
BTIG, and
Oppenheimer have reiterated their 'buy' position on BSX due to strong market opportunity and positive Q2 results. As for its products, the
Bolt IVL study is projected to be a game-changer for the company. On their operation side,
Boston Scientific announced successful completion of a €1.5 billion offering of senior notes. The company also released its Q2 earnings, exceeding expectations and leading to a stock rise. Despite oscillations in the market, many consider BSX to be a top pick in low volatility stocks.
Boston Scientific Corp BSX News Analytics from Wed, 26 Feb 2025 08:00:00 GMT to Sat, 27 Sep 2025 10:42:32 GMT -
Rating 7
- Innovation 7
- Information 7
- Rumor -3
